Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 7, Issue 2, 2025

Current Status and Research Progress of Integrated Traditional Chinese and Western Medicine in the Diagnosis and Treatment of Atrial Fibrillation

Download as PDF

DOI: 10.23977/medcm.2025.070220 | Downloads: 14 | Views: 186

Author(s)

Na Li 1, Jinli Liu 2, Mei Yang 2

Affiliation(s)

1 Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610032, China
2 Neijiang Hospital of Traditional Chinese Medicine Affiliated to Chengdu University of Traditional Chinese Medicine, Neijiang, Sichuan, 641099, China

Corresponding Author

Jinli Liu

ABSTRACT

Atrial Fibrillation (AF) is a common arrhythmia in clinical practice, which seriously affects the quality of life of patients and significantly increases the risks of death, stroke, heart failure and dementia. Over the past two decades, a series of breakthroughs have been made in areas such as risk prediction and screening diagnosis of AF, stroke prevention, rhythm control, catheter ablation and comprehensive management. To further promote the standardized management of AF and promptly and fully apply new technologies and concepts to clinical practice, Chinese Society of Cardiology (CSC) and Chinese Heart Rhythm Society (CHRS) organized experts to jointly formulate the "Chinese Guidelines for the Diagnosis and Treatment of Atrial Fibrillation", which elaborated on all aspects of AF management and provided a reference for standardized clinical diagnosis and treatment. However, the author believes that its treatment is confronted with problems such as side effects of Western medicine, high recurrence rate of surgery, and complex anticoagulation management, while traditional Chinese medicine has shown unique advantages through holistic dialectics and multi-target regulation. Integrated treatment of traditional Chinese and Western medicine can achieve synergistic effects, but currently there is a lack of systematic review and integration mechanism research and clinical evidence. This paper focuses on investigating the theoretical basis, mechanisms of action, and clinical applications of integrated Chinese-Western medicine in AF management, aiming to establish a foundation for therapeutic optimization.

KEYWORDS

Atrial Fibrillation, epidemiology, pathogenesis, Western medicine treatment, Traditional Chinese medicine treatment

CITE THIS PAPER

Na Li, Jinli Liu, Mei Yang, Current Status and Research Progress of Integrated Traditional Chinese and Western Medicine in the Diagnosis and Treatment of Atrial Fibrillation. MEDS Chinese Medicine (2025) Vol. 7: 151-162. DOI: http://dx.doi.org/10.23977/medcm.2025.070220.

REFERENCES

[1] Huang Congxin, Zhang Shu, Huang Dejia, et al. Atrial Fibrillation: Current Understanding and Recommendations for Treatment-2018 [J]. Chinese Journal of Cardiac Pacing and Electrophysiology, 2018, 32 (04): 315-368. 
[2] Jiang Junrong, Xue Yumei. Anticoagulation in atrial fibrillation[J]. Chinese Journal of Practical Internal Medicine, 2023, 43(2): 106-109. 
[3] Wang Yanpeng, Li Jingbo. Interpretation of the "Chinese Guidelines for the Diagnosis and Treatment of Atrial Fibrillation[J]. "CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT, 2024, 24(11): 5-9. 
[4] National Center for Cardiovascular Diseases, The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on Cardiovascular Health and Diseases in China 2023: an Updated Summary[J]. Chinese Circulation Journal, 2024, 39(7): 625-660. 
[5] Li Yichong, Liu Shiwei, Zeng Xinying, Zhou Maigeng. Report on Burden of Cardiovascular Diseases From 1990 to 2016 in China[J]. Chinese Circulation Journal, 2019, 34(8): 729-740. 
[6] Liu S, Li Y, Zeng X, et al. Burden of Cardiovascular Diseases in China, 1990-2016: Findings From the 2016 Global Burden of Disease Study[J]. JAMA Cardiol, 2019, 4(4): 342-352. 
[7] Tsao C W, Aday A W, Almarzooq Z I, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association[J]. Circulation, 2023, 147(8): e93-e621. 
[8] Joseph L. Dieleman, Jackie Cao, et al. US Health Care Spending by Payer and Health Condition, 1996-2016 [J]. JAMA, 2020, 323(9):863-884. 
[9] Li Han, Cai Wei. Progress in pathogenesis and treatment of atrial fibrillation[J]. Journal of Practical Electrocardiology, 2024, 33(1): 87-92. 
[10] Que Dongdong, Song Xudong. Roles of atrial remodeling in atrial fibrillation[J]. Journal of Practical Electrocardiology, 2021, 30(6): 404-407. 
[11] Hu J, Zhang J, Li L, et al. PU. 1 inhibition attenuates atrial fibrosis and atrial fibrillation vulnerability induced by angiotensin-II by reducing TGF-beta1/Smads pathway activation[J]. Journal of Cellular and Molecular Medicine, 2021(8): 6746-6759. 
[12] Wang Yao, Chen Guiying. Research progress of renin angiotensin system and atrial fibrillation[J]. Hebei Medical Journal, 2022, 44(2): 278-281+288. 
[13] Liew R, Khairunnisa K, Gu Y, et al. Role of tumor necrosis factor-alpha in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate[J]. Circ J, 2013, 77(5): 1171-1179. 
[14] Zhou Shuye, Xie Meili, Wang Zhihao. Research Progress on the Relationship Between Inflammation and Atrial Fibrillation[J]. International Journal of Geriatrics, 2022, 43(6): 742-746. 
[15] Qin M, Zeng C, Liu X. The cardiac autonomic nervous system: A target for modulation of atrial fibrillation[J]. Clin Cardiol, 2019, 42(6): 644-652. 
[16] Xi Yutao, Cheng Jie. Dysfunction of the autonomic nervous system in atrial fibrillation[J]. Journal of thoracic disease, 2015, 7(2):193-198. 
[17] Ye Q, Liu Q, Ma X, et al. MicroRNA-146b-5p promotes atrial fibrosis in atrial fibrillation by repressing TIMP4[J]. J Cell Mol Med, 2021, 25(22): 10543-10553. 
[18] Han X, Wang S, Yong Z, et al. miR-29b ameliorates atrial fibrosis in rats with atrial fibrillation by targeting TGFbetaRIota and inhibiting the activation of Smad-2/3 pathway[J]. J Bioenerg Biomembr, 2022, 54(2): 81-91. 
[19] Hu Hu, Wu Tao, et al. Effects of miR-145 on the Atrial Effective Refractory Period, Atrial Fibrillation Induction Rate and Atrial Electrical Remodeling in a Rapid Atrial Pacing Model of New Zealand Big-Eared White Rabbits[J]. Molecular Cardiology of China, 2022, 22(1): 4495-4500. 
[20] Zhang Song, et al. Resveratrol reduces electrical remodeling in atrial fibrillation by downregulating microRNA-21 in neonatal rat atrial myocytes[J]. Chinese Journal of Pathophysiology, 2017, 33(8): 1353-1358. 
[21] Wong C X, Sullivan T, Sun M T, et al. Obesity and the Risk of Incident, Post-Operative, and Post-Ablation Atrial Fibrillation: A Meta-Analysis of 626, 603 Individuals in 51 Studies[J]. JACC Clin Electrophysiol, 2015, 1(3): 139-152. 
[22] January C T, Wann L S, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons[J]. Circulation, 2019, 140(2): e125-e151. 
[23] Dong Xue, et al. Research Progress on the Pathogenesis and Treatment of Atrial Fibrillation in Patients with Obstructive Sleep Apnea-Hypopnea Syndrome[J]. Shandong Medical Journal, 2022, 62(30): 111-114.
[24] Liu Guangzhong. Risk factors analysis and strategies of prevention and treatment of atrial fibrillation[J]. China Journal of Modern Medicine, 2022, 32(7): 1-5.
[25] Xie Yong, Wang Jingfeng. Application of Antiarrhythmic Drugs in Rhythm Control for Atrial Fibrillation[J]. Chinese Journal of Cardiac Arrhythmias, 2025, 29(02): 89-93. 
[26] Li Jingdong, Xia Chaorui, Chen Yuan. Progress of electrophysiology and the clinical application of dronedarone[J]. Journal of Clinical Cardiology, 2022, 38(3): 172-176. 
[27] Huang Guanming, Wang Jingjing, et al. Exploration of Pathogenesis and Treatment Strategies for Atrial Fibrillation Recurrence After Catheter Ablation Based on“Unity of Body and Spirit”[J]. Jiangsu Journal of Traditional Chinese Medicine, 2025, 57(5): 21-24.
[28] Hauk L. Newly Detected Atrial Fibrillation: AAFP Updates Guideline on Pharmacologic Management[J]. American Family Physician, 2017, 96(5): 332-333. 
[29] Zhang Linbo, Rong Chao, et al. Research Progress of Atrial Fibrillation in Traditional Chinese Medicine and Western Medicine[J]. Henan Traditional Chinese Medicine, 2024, 44(5): 790-796. 
[30] Ye Haitao, et al. Observation on Therapeutic Effect of  Zhigancao Decoction Combined with Metoprolol on Persistent Atrial Fibrillation[J]. World Journal of Integrated Traditional and Western Medicine2021, 16(4): 731-735.
[31] Ji Meng, et al. Clinical Observation on the Treatment of Non-Valvular Paroxysmal Atrial Fibrillation with Self-Prescribed Chaihu Jia Longgu Muli Decoction Derivative Based on the Pathogenesis Theory of“Mutual Fanning of Liver Wind and Heart Fire"[J]. Journal of Nanjing University of Traditional Chinese Medicine, 2025, 41(3): 405-410.
[32] Xiang Na, Hu Jiayun, Wu Bin, et al. Research Progress on the Treatment of Atrial Fibrillation with Shensong Yangxin Capsule[J]. Chinese Journal of Cardiac Pacing and Electrophysiology, 2024, 38(6): 391-396. 
[33] Li Min, et al. The Clinical Study of Wenxin Keli in the Treatment of Atrial Fibrillation: a Systematic Review[J]. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology, 2018, 20(10): 1761-1771. 
[34] Xie Hongjuan, Fu Haiying, Zhu Caifeng, et al. Effects of Danshen Injection(Salvia miltiorrhiza) on Pharmacodynamics and Pharamcokinetics of Warfarin in Rats[J]. Herald of Medicine, 2009, (01): 41-44.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 8493
Visits: 470723

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.